Ii-key/MHC class II epitope hybrid peptide immunomodulator peptide vaccines (NuGenerex Immuno-Oncology)

N/A

Report date: 2025/03/20 15:01:04

Base Information

Drug NameIi-key/MHC class II epitope hybrid peptide immunomodulator peptide vaccines (NuGenerex Immuno-Oncology)

Drug Alias NameIi-Key Hybrid MHC Class II peptides (Antigen Express)Ii-key/MHC class II epitope hybrid peptide immunomodulator peptide vaccines (Antigen Express)immunomodulators (Antigen Express)Ii-key/MHC class II epitope hybrid peptide immunomodulators (Antigen Express)Ii key hybrid peptide immunomodulators (Antigen Express) +[6]

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine

Mechanisms of ActionHistocompatibility antigens class II modulators

TargetsHistocompatibility antigens class II

Therapy Area/IndicationsDiabetes Mellitus, Type 1

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNugenerex Immuno-Oncology Inc

China Registration ClassN/A

Develop Information

Active CompaniesNugenerex Immuno-Oncology Inc

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 1

Inactive IndicationsN/A

Other Information

ATC CodeN/A